Xylometazoline (hydrochloride)

Xylometazoline hydrochloride is an α-adrenergic receptor agonist (Ki=0.05-1.7 μM) . Xylometazoline hydrochloride can constrict nasal blood vessels and increase nasal airflow. Xylometazoline hydrochloride can be used in nose stuffiness and runny nose research[1][2][3][4].

Product Specifications

CAS Number

[1218-35-5]

UNSPSC

12352005

Hazard Statement

H301

Target

Adrenergic Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/xylometazoline-hydrochloride.html

Purity

99.94

Solubility

DMSO : 25 mg/mL (ultrasonic) |H2O : 50 mg/mL (ultrasonic)

Smiles

CC1=C(CC2=NCCN2)C(C)=CC(C(C)(C)C)=C1.Cl

Molecular Formula

C16H25ClN2

Molecular Weight

280.84

Precautions

H301

References & Citations

[1]Ronald Eccles, et al. The nasal decongestant effect of xylometazoline in the common cold. Am J Rhinol. 2008 Sep-Oct;22 (5) :491-6.|[2]Britta Haenisch, et al. Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24 (6) :729-39.|[3]M Kar, et al. Development of an intranasal formulation containing indomethacin and xylometazoline for rhinosinusitis treatment. Eur Rev Med Pharmacol Sci. 2022 Dec;26 (2 Suppl) :65-71.|[4]Ayse Ipek Akyuz Unsal, et al. Ophthalmic adverse effects of nasal decongestants on an experimental rat model. Arq Bras Oftalmol. 2018 Jan-Feb;81 (1) :53-58.